Dysregulation of bacterial proteolytic machinery by a new class of antibiotics

Nature Medicine

Volumn 11, Issue 10, 2005, Pages 1082-1087

  Brötz Oesterhelt, Heike ^a   Beyer, Dieter ^a   Kroll, Hein Peter ^a   Endermann, Rainer ^a   Ladel, Christoph ^a,d   Schroeder, Werner ^a   Hinzen, Berthold ^a   Raddatz, Siegfried ^a   Paulsen, Holger ^a   Henninger, Kerstin ^a   Bandow, Julia E ^b,e   Sahl, Hans Georg ^c   Labischinski, Harald ^a,f  

^a BAYER PHARMA AG   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d Merck Serono SpA   (Italy)

^e PFIZER INC   (United States)

^f MerLion Pharmaceuticals GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLDEPSIPEPTIDE ANTIBIOTIC; ADENOSINE TRIPHOSPHATASE; ANTIBIOTIC AGENT; ENDOPEPTIDASE CLP; PROTEINASE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL INFECTION; CELL DEATH; CELL DIVISION; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACILLUS SUBTILIS; BACTERIA; DEPSIPEPTIDES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENDOPEPTIDASE CLP; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FEMALE; MICE; MOLECULAR STRUCTURE; MUTATION; PNEUMOCOCCAL INFECTIONS; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; RATS, WISTAR; SEPSIS;

BACTERIA (MICROORGANISMS); POSIBACTERIA; RODENTIA;

EID: 27144460621     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1306     Document Type: Article

References (24)

1. Levy, S. & Marshall, B. Antibacterial resistance worldwide: causes, challenges, responses. Nat. Med. 10, S122-S129 (2004).
2. Infectious Diseases Society of America. Bad bugs, no drugs. As antibiotic discovery stagnates, a public health crisis brews. IDSA 〈http://www. idsociety.org/pa/IDSA_Paper4_final_web.pdf〉 (2004).
3. Hiramatsu, K. et al. New trends in Staphylococcus aureus infections: glycopeptide resistance in hospital and methicillin resistance in the community. Curr. Opin. Infect. Dis. 15, 407-413 (2002).
4. Weigel, L. et al. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science 302, 1569-1571 (2003).
5. Appelbaum, P.C. Resistance among Streptococcus pneumoniae: Implications for drug selection. Clin. Infect. Dis. 34, 1613-1620 (2002).
6. Michel, K.H. & Kastner, R.E. A54556 antibiotics and process for production thereof. US patent 4492650 (1985).
7. Hardy, C. & Cozzarelli, N. Alteration of Escherichia coli topoisomerase IV to novobiocin resistance. Antimicrob. Agents Chemother. 47, 941-947 (2003).
8. Tsubery, H., Ofek, I., Cohen, S., Eisenstein, M. & Fridkin, M. Modulation of the hydrophobic domain of polymyxin B nonapeptide: effect on outer-membrane permeabilization and lipopolysaccharide neutralization. Mol. Pharmacol. 62, 1036-1042 (2002).
9. Maurizi, M.R., Thompson, M.W., Singh, S.K. & Kim, S.H. Endopeptidase Clp: ATP-dependent Clp protease from Escherichia coli. Methods Enzymol. 244, 314-331 (1994).
10. Wang, J., Hartling, J.A. & Flanagan, J.M. The structure of ClpP at 2.3 A resolution suggests a model for ATP-dependent proteolysis. Cell 91, 447-456 (1997).
11. Msadek, T. et al. ClpP of Bacillus subtilis is required for competence development, motility, degradative enzymes synthesis, growth at high temperature and sporulation. Mol. Microbiol. 27, 899-914 (1998).
12. Porankiewicz, J., Wang, J. & Clarke, A.K. New insights into the ATP-dependent Clp protease: Escherichia coli and beyond. Mol. Microbiol. 32, 449-458 (1999).
13. Thompson, M.W., Singh, S.K. & Maurizi, M.R. Processive degradation of proteins by the ATP-dependent Clp protease from Escherichia coli. Requirement for the multiple array of active sites in ClpP but not ATP hydrolysis. J. Biol. Chem. 269, 18209-18215 (1994).
14. Woo, K.M., Chung, W.J., Ha, D.B., Goldberg, A.L. & Chung, C.H. Protease Ti from Escherichia coli requires ATP hydrolysis for protein breakdown but not for hydrolysis of small peptides. J. Biol. Chem. 264, 2088-2091 (1989).
15. Schlothauer, T., Mogk, A., Dougan, D.A., Bukau, B. & Turgay, K. MecA, an adaptor protein necessary for ClpC chaperone activity. Proc. Natl. Acad. Sci. USA 100, 2306-2311 (2003).
16. Bandow, J.E., Brötz, H., Leichert, L.I., Labischinski, H. & Hecker, M. Proteomic approach to understanding antibiotic action. Antimicrob. Agents Chemother. 47, 948-955 (2003).
17. Hecker, M., Schumann, W. & Völker, U. Heat-shock and general stress response in Bacillus subtilis. Mol. Microbiol. 19, 417-428 (1996).
18. Gerth, U. et al. Fine-tuning in regulation of Clp protein content in Bacillus subtilis. J. Bacteriol. 186, 179-191 (2004).
19. Kock, H., Gerth, U. & Hecker, M. MurAA, catalysing the first committed step in peptidoglycan biosynthesis, is a target of Clp-dependent proteolysis in Bacillus subtilis. Mol. Microbiol. 51, 1087-1102 (2004).
20. Fritsche, T., Sader, H., Cleeland, R. & Jones, R. Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance. Antimicrob. Agents Chemother. 49, 1468-1476 (2005).
21. Kwon, H. et al. Effect of heat shock and mutations in ClpL and ClpP on virulence gene expression in Streptococcus pneumoniae. Infect. Immun. 71, 3757-3765 (2003).
22. Kwon, H. et al. The ClpP protease of Streptococcus pneumoniae modulates virulence gene expression and protects against fatal pneumococcal challenge. Infect. Immun. 72, 5646-5653 (2004).
23. Hensel, M. et al. Simultaneous identification of bacterial virulence genes by negative selection. Science 269, 400-403 (1995).
24. Anagnostopoulos, C. & Spizizen, J. Requirements for the transformation in Bacillus subtilis. J. Bacteriol. 81, 741-746 (1961).